

PKS Holdings Limited (ASX: PKS) Sydney, 13 April 2021

### **Directors Interest Notices**

PKS Holdings Limited (ASX: PKS) ("PKS" or the "Company") advises, that due to an administrative oversight the attached Directors Interest Notices were not released with the announcement in relation to the change of Directors. The Board understands the importance of the need to ensure compliance with the Listing Rules and is confident that adequate processes are in place to ensure compliance with Listing Rule 3.19B.

Authorised for the release by the Chairman of the Board.

-END-

For further information please contact:

Tim Kelsey CEO PKS Holdings Phone: 0476 835 311 Mike Hill Chairman, PKS Holdings Phone: 0421 056 691

### About PKS

PKS is an Australian Healthcare company that works with health organisations around the world to better capture, manage and leverage their human expertise to improve the performance of their business and deliver better patient outcomes. PKS' products have a broad range of applications across the healthcare services industry. The key value propositions of the PKS' suite of software applications focus on and have the potential to:

- Clinical Decision Support, which enables better decision making, leading to improved patient outcomes and a reduction in medical errors;
- Improve operational efficiency, with opportunities for significant cost savings and revenue improvements;
- Improve the quality of data, which makes the billing processes in healthcare organisations more accurate and more efficient; and
- Leverage off data analytics and benchmarking, which provides insights into healthcare data and enables healthcare organisations to improve the quality of patient care.

With the recent acquisition of Pavilion Health, the suite of software products now consists of:

• RippleDown<sup>®</sup> enables any clinical domain expert – typically a pathologist or clinician – to automate their unique, human decision-making process at scale in order to provide real-time

clinical analysis, interpretations and treatment recommendations. By aggregating and analysing all available patient information – including current and historical results – RippleDown<sup>®</sup> is able to provide a holistic view of patients to generate the most comprehensive and patient-specific interpretations and recommendations.

- RippleDown<sup>®</sup> is managed by domain experts, not IT, enabling rules to be built quickly and easily to ensure the system remains updated and relevant.
- PICQ<sup>®</sup> is an auditing tool used in hospitals that assesses every record clinically coded for data quality. It measures data accuracy against indicators and identifies records for correction and uses a set of pre-determined indicators created and maintained by PKS' subject-matter experts to identify records that may be incorrectly coded.
- RISQ<sup>™</sup> Reviews records in datasets to assess the quality of Condition Onset Flags (COF) data and incidences of hospital-acquired complications (HACs). It provides a method to benchmark hospitals against statistical peers to provide industry benchmarks of HAC incidence and underlying data quality.
- Codexpert<sup>™</sup> is a web-based eBook application providing the full health-data classification reference for clinical coding of patient episodes.

Rule 3.19A.3

## Appendix 3Z

### **Final Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	PKS Holdings Limited
ABN	42 627 071 121

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Ronald van der Pluijm
Date of last notice	6 June 2019
Date that director ceased to be director	17 March 2021

**Part 1 – Director's relevant interests in securities of which the director is the registered holder** *In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust* 

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

#### Number & class of securities

800,000 unlisted and unvested options, each exercisable at 20 cents, expiring on 29/05/2024.

800,000 unlisted and unvested performance rights, expiring on 29/05/2024

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2 - Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest	Number & class of securities
Perfume Only Pty Ltd <tiger a="" c=""></tiger>	398,312 fully paid ordinary shares

### Part 3 – Director's interests in contracts

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
No. and class of securities to which interest relates	N/A

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3X

Rule 3.19A.1

## **Initial Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	PKS Holdings Limited	
ABN	42 627 071 121	

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	James Birch
Date of appointment	17 March 2021

## Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

### Number & class of securities

Nil

<sup>+</sup> See chapter 19 for defined terms.

### Part 2 – Director's relevant interests in securities of which the director is not

### the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest.	Number & class of Securities
Nil	Nil

### Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
No. and class of securities to which interest relates	N/A

<sup>+</sup> See chapter 19 for defined terms.